Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Depth over breadth: Piramal Consumer Healthcare takes a leaf out of the modern FMCG playbook
The company is cutting new product launches by half and doubling down on quick commerce to chase a $200 million revenue target by 2030, CEO Sai Ramana Ponugoti told Mint.
Missed the FII U-turn? 6 stocks turned multibagger after foreign investors corrected their mistake
Foreign institutional investors (FIIs) reversed their selling trend in six select Indian stocks, turning them into multibaggers. Bajaj Consumer Care led the pack with a 265% surge after FIIs significantly increased their stake. Other beneficiaries include Acutaas Chemicals, SML Mahindra, Dee Development Engineers, United Foodbrands, and RateGain Travel Technologies, all witnessing substantial gains following FII re-entry. This shift highlights smart money's strategic course correction.
Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise value
Mamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This strategic move, Honasa's second acquisition in under a year, signals a growing trend of consolidation in the beauty and personal care sector. Honasa aims to integrate science-backed skincare with nutraceuticals, addressing consumer demand for holistic wellness solutions. Fluence Pharma will become the ninth brand under Honasa's umbrella.
Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence Pharma
Honasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry into the health and wellness supplements market. This strategic move aims to leverage Fluence's patented technology and dermatologist network to expand Honasa's 'inside-out' beauty solutions. The acquisition is expected to significantly boost Honasa's growth by diversifying its product portfolio into the rapidly expanding Indian nutraceuticals sector.
Worst is behind us, markets could hit new highs in 6-12 months: Envision’s Nilesh Shah
Nilesh Shah, Founder of Envision Capital, remains positive on digital platforms, defence, aerospace and consumer discretionary sectors, citing long-term domestic growth drivers. Shah expects stronger earnings, policy reforms and foreign investor participation to support markets, while also identifying opportunities linked to GLP-1 drugs, nutrition products and healthcare themes.
RBI Governor urges banks to treat MSMEs as long-term business partners
Reserve Bank Governor Sanjay Malhotra on Monday asked banks and lending institutions to internalise a fundamental reorientation in their approach towards MSMEs, and view them as long-term business partners rather than just a regulatory obligation. He said MSMEs collectively contribute 31 per cent of GDP, account for approximately 35 per cent of manufacturing output, and represent close to half of India's merchandise exports, while sustaining livelihoods for over 32 crore people. He also asked MSMEs to take ownership of growth by investing in technology, R&D and innovation as consumer preferences and expectations evolve, engage actively with RBI through their instruments and build and sustain relationships with your stakeholders creditors, suppliers and customers.
Sensex rises 291 points, Nifty tops 24,100 on cooling crude and FII support
Domestic equities advanced on Monday as cooling oil prices and fresh FII inflows fuelled risk appetite. Buying in heavyweight Reliance Industries and healthcare counters propelled the Nifty past the 24,100 level. The gains were partly offset by weakness in consumer durables and FMCG stocks.
Nomura expects shares of this drugmaker to rise 37% on renewed branded generics, consumer biz focus
Nomura, in its note, said that Dr. Reddy's Laboratories has sharpened its focus on branded generics and consumer business, a shift reflected in acquisitions, organic investments and recent changes to the management council.
HealthQuad looking at deeper opportunities in new age healthcare with its Fund III
The early growth investor sees a wider and deeper opportunity across new age healthcare models, as demand and the pipeline of entrepreneurs building stronger, lasting businesses continues to grow
Bata India appoints Sanjay Rao as MD & CEO
Bata India has announced Sanjay Rao will take over as Managing Director and Chief Executive Officer effective on August 24, 2026. He replaces Gunjan Shah. Rao brings over two decades of retail and consumer leadership experience from international markets. Bata Group sees India as a key growth market. Rao's appointment aims to drive consumer relevance and product strength for Bata India.
P&G India flags pressure on consumer demand, input costs
Procter and Gamble India sees rising costs and softening urban demand, with company executives saying inflation will impact consumer spending. However, despite near-term challenges, P&G maintains a positive long-term outlook for India.
Cipla appoints health chief Shivam Puri to lead One India business
Cipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take effect from July 1. Puri currently heads Cipla Health, a role he has held since 2019. His extensive experience in consumer goods and healthcare will now steer Cipla's domestic operations.